Analyst Price Target is $14.67
▲ +38.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Theravance Biopharma in the last 3 months. The average price target is $14.67, with a high forecast of $19.00 and a low forecast of $11.00. The average price target represents a 38.10% upside from the last price of $10.62.
Current Consensus is
The current consensus among 3 contributing investment analysts is to hold stock in Theravance Biopharma. This rating has held steady since July 2021, when it changed from a Buy consensus rating.
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.